GlassScriptPhysician profile
Eva Marie Wolf
NPI 1437578069
$3,317.44
in general payments reported to CMS, 2019-2025
23 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $59.14 · 2021: $270 · 2022: $57.73 · 2023: $624 · 2024: $1,042 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,797.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,203.08 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $698.48 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $300.95 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $180.11 | 2022-2025 | |
| W. L. Gore & Associates, INC. | $162.20 | 2025 | Gore Synecor Preperitoneal Biomaterial |
| Exact Sciences Corporation | $150.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $140.30 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Dexcom, INC. | $69.69 | 2023-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $67.46 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $49.48 | 2025 | Lagevrio |
| Esperion Therapeutics, INC. | $43.24 | 2025 | Nexletol |
| Amgen INC. | $41.13 | 2024-2025 | Otezla, Repatha, Repatha |
| Davol INC. | $39.12 | 2025 | Phasix Mesh |
| Astellas Pharma US INC | $28.06 | 2024 | Veozah |
| Axsome Therapeutics, INC. | $25.74 | 2025 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $25.08 | 2025 | |
| Idorsia Pharmaceuticals US INC | $18.14 | 2023 | Quviviq |
| Abbvie INC. | $14.20 | 2025 | |
| Novartis Pharmaceuticals Corporation | $12.75 | 2019 | |
| Shire North American Group INC | $12.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.13 | 2021 | |
| Sanofi Pasteur INC. | $11.96 | 2019 | |
| Allergan, INC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.